Top Stories

Grid List

WuXi Biologics a global leadingopen-access biologics technology platform company offering end-to-end solutions for biologicsdiscovery, development and manufacturing,

InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden.

Achieve Life Sciences, Inc. a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program.

BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 (Astarabine) in acute leukemia patients.

Acasti Pharma Inc announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma.

Sartorius Stedim Biotech (SSB), a leading international supplier to the biopharmaceutical industry announced an agreement with Nova Biomedical (Nova), a well-known US manufacturer of cell culture analyzers, to integrate their BioProfile® FLEX2 into the ambr® multi-parallel bioreactor systems for automated, at-line cell culture analytics.

Contract development and manufacturing organisation (CDMO) Saneca Pharma has been granted a multiple dosage form approval for the manufacture and supply of solids, semi-solids and liquid finish dose products to Russia.

Manufacturers require high code accuracy and legibility from their Thermal Transfer Overprinters to improve production line efficiency and reduce overall costs.

With the recent increase in health consciousness globally, the concept of "farm to fork" has swept the world. As a result of this, the search for methods to reduce food loss and waste in the supply chain from the farm to the dining table, has becomea critical problem to solve; from the perspectives of both economics and environmental protection.

A Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with the installation of new automatic capsule filling capabilities at its EU-GMP approved plant in Pamplona, Spain.

Market Movers

Rogers Corporation

NYQ : ROG - 22 Aug, 9:59am
112.43
-0.21 (-0.19%) After Hours:
Open 112.82 Mktcap 2.04B
High 113.52 52wk Hight 123.38
Low 112.22 52wk Low 51.98
Vol 6413 Avg Vol 121844
Eps 5.55 P/e 27.11
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 22 Aug, 10:00am
6.469
+0.029 (+0.450%) After Hours:
Open 6.430 Mktcap 99.50B
High 6.476 52wk Hight 6.990
Low 6.420 52wk Low 4.190
Vol 683762 Avg Vol 6.94M
Eps 0.490 P/e 12.160
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 22 Aug, 10:00am
62.33
+0.36 (+0.58%) After Hours:
Open 61.97 Mktcap 170.00B
High 62.34 52wk Hight 66.80
Low 61.92 52wk Low 58.29
Vol 632731 Avg Vol 8.24M
Eps 3.87 P/e 33.75
Currency: USD

Johnson & Johnson

NYQ : JNJ - 22 Aug, 10:00am
133.14
-0.31 (-0.23%) After Hours:
Open 133.27 Mktcap 357.35B
High 133.85 52wk Hight 137.08
Low 132.90 52wk Low 109.32
Vol 501116 Avg Vol 5.52M
Eps 7.18 P/e 22.53
Currency: USD

Pfizer, Inc.

NYQ : PFE - 22 Aug, 10:00am
32.93
+0.17 (+0.52%) After Hours:
Open 32.76 Mktcap 195.85B
High 33.00 52wk Hight 35.38
Low 32.70 52wk Low 29.83
Vol 1.24M Avg Vol 18.42M
Eps 2.56 P/e 24.09
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 22 Aug, 9:49am
13.63
+0.02 (+0.15%) After Hours:
Open 13.63 Mktcap
High 13.63 52wk Hight 16.29
Low 13.63 52wk Low 12.79
Vol 101 Avg Vol 4272
Eps P/e
Currency: USD

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery,has announced a £7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual.

The Mundipharma network of independent associated companies announced that it has acquired from CellAct the worldwide development, commercialization and manufacturing rights to CAP7.1.

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

In recent years the pharmaceutical industry has seen a significant change to the way its manufacturersand supply chains operate, due to the establishment of several serialization and track and trace regulations mandated globally.

Patient-centricity has become an important focus for drug developers and an essential element of clinical studies aimed at showing that a new therapy addresses real patient needs. How companies define patient-centric trials sometimes differ.

Clinical trials are evolving away from trials based solely at investigator sites, moving on to the patient’s home, requiring direct-to-patient services in order for patients to participate.